Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that safety and tolerability data from Part 1 of its ProstACT Global ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE